Nebula Genomics

Executive Summary

Nebula Genomics, founded in 2017 and based in San Francisco, is a direct-to-consumer (D2C) personal genomics company that differentiates itself through a strong focus on privacy and whole genome sequencing (WGS) rather than genotyping. Its D2C offering provides deep ancestry analysis, health reports, and data exploration tools, all underpinned by advanced privacy protections that allow users to control their genetic data. Beyond the consumer segment, Nebula operates a B2B research arm that partners with biotech and pharmaceutical companies to facilitate genetic studies, leveraging its growing database of consented genomic data. This dual-revenue model positions Nebula to benefit from both the expanding consumer genomics market and the increasing demand for real-world genomic data in drug development. The company's emphasis on whole genome sequencing, which captures more comprehensive genetic information than genotyping arrays, provides a competitive edge in data depth and research utility. Nebula's privacy-centric approach may also appeal to consumers wary of data misuse, a key differentiator from competitors like 23andMe and AncestryDNA. However, the D2C genomics space remains highly competitive and faces regulatory scrutiny, and Nebula's financials and valuation are not publicly disclosed. The company's ability to scale its B2B partnerships and drive consumer adoption will be critical to long-term growth.

Upcoming Catalysts (preview)

• Q3 2026Major B2B partnership with a top-20 pharma company for genetic research40% success
• Q2 2026Launch of new health reports leveraging polygenic risk scores for common diseases70% success
• Q4 2026Series B or later funding round to scale operations and marketing50% success